Patents by Inventor Ursula Puntener

Ursula Puntener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
    Publication number: 20230212303
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: August 24, 2022
    Publication date: July 6, 2023
    Applicant: Roche GlycArt AG
    Inventors: Pablo UMAÑA, Peter Brúnker, Claudia Ferrara Koller, Tobias Suter, Ursula Púntener, Ekkehard Móssner
  • ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
    Publication number: 20210002382
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: February 11, 2020
    Publication date: January 7, 2021
    Applicant: Roche Glycart AG
    Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER
  • Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
    Patent number: 9296820
    Abstract: The present invention relates to nucleic acids encoding anti-CD20 antigen binding molecules (ABMs). In particular embodiments, the present invention relates to nucleic acid encoding recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. In addition, the present invention relates to vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: March 29, 2016
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrara Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
    Publication number: 20160075794
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Inventors: Pablo UMAÑA, Peter Brünker, Claudia FERRARA KOLLER, Tobias SUTER, Ursula Püntener, Ekkehard Mössner
  • ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
    Publication number: 20160076009
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER
  • ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
    Publication number: 20160075793
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER
  • Antigen binding molecules with increased Fc receptor binding affinity and effector function
    Patent number: 8883980
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 11, 2014
    Assignee: Roche Glycart AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • Antigen binding molecules with increased Fc receptor binding affinity and effector function
    Publication number: 20090010921
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 8, 2009
    Applicant: GlycArt Biotechnology AG
    Inventors: Pablo Umana, Peter Brunker, Claudia Ferrara, Tobias Suter, Ursula Puntener, Ekkehard Mossner
  • Antigen binding molecules with increased Fc receptor binding affinity and effector function
    Publication number: 20050123546
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: November 5, 2004
    Publication date: June 9, 2005
    Applicant: GlycArt Biotechnology AG
    Inventors: Pablo Umana, Peter Brunker, Claudia Ferrara, Tobias Suter, Ursula Puntener, Ekkehard Mossner